The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients

British Journal of Cancer

Volumn 110, Issue 10, 2014, Pages 2524-2530

  Krenn Pilko, S ^a   Langsenlehner, U ^b   Thurner, E M ^a   Stojakovic, T ^a   Pichler, M ^c   Gerger, A ^a   Kapp, K S ^a   Langsenlehner, T ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Division of Internal Medicine   (Austria)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; THROMBOCYTE COUNT;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MIDDLE AGED; PLATELET COUNT; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SAMPLE SIZE;

EID: 84900547143     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.163     Document Type: Article

References (49)

1. Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmueller M, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A (2013) A derived neutrophil to lymphocyte ratio predicts clinical outcome in sta ge II and III colon cancer patients. Br J Cancer 109: 395-400.
2. Albain KS, BarlowWE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF (2010) Prognostic and predictive value of the 21-gene recurrence score assay in post menopausal women with nodepositive, oestrogen-receptor- positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11: 55-65.
3. Alexandrakis MG, Passam FH, Moschandrea IA, C hristophoridou AV, Pappa CA, Coulocheri SA, Kyriakou DS (2003) Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 26: 135-140.
4. Asher V, Lee J, Innamaa A, Bali A (2011) Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol 13: 499-503.
5. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, Habeshy A, Picon A, Bloom S (2013) Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol 30: 432.
6. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY (2003) Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth fact or in hormone-refractory metastatic breast cancer patients. Br J Cancer 88: 1721-1726.
7. Balkwill F, Mantovani A (2001) Inflammation and cancer: Back to Virchow Lancet 357: 539-545.
8. B enoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY (2002) Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2: 311-315.
9. Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, Robertson JF, Mitchell MJ, Ball GR, Haybittle JL, Elston CW (2007) Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases dia gnosed in 1990-1999. Eur J Cancer 43: 1548-1555.
10. Carruthers R, Tho LM, Brown J, Kakumanu S, McCartney E, McDonald AC (2012) Systemic inflammatory response is a predictor of outcome in patients under going preoperative chemoradiation for locally advanced rectal cancer. Colorectal Dis 14: 701-707.
11. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867.
12. Dethle fsen C, Højfeldt G, Hojman P (2013) The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 138: 657-664.
13. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, G uarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F (2014) Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multic enter study. Ann Oncol 25: 611-618.
14. Drukker CA, Bueno-de-Mesquita JM, Retèl VP, Van HartenWH, Van Tinteren H, Wesseling J, Roumen RM, Knauer M, Van ?t Veer LJ, Sonke GS, Rutgers EJ, Van De Vijver MJ, Linn SC (2013) A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 133: 929-936.
15. Egan K, Crowley D, Smyth P, O ?Toole S, Spillane C, Martin C, Gallagher M, Canney A, Norris L, Conlon N, McEvoy L, Ffrench B, Stordal B, Keegan H, Finn S, McEneaney V, Laios A, Ducré e J, Dunne E, Smith L, Berndt M, Sheils O, Kenny D, O?Leary J (2011) Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One 6: E26125.
16. Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Porrata LF (2008) Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: A retrospective study. Br J Haematol 141: 792-79 8.
17. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2012) Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403.
18. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, Pedrazzoli S, Plebani M (2006) Decreased total lym phocyte counts in pancreatic cancer: An index of adverse outcome. Pancreas 32: 22-28.
19. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Panel members (2011) Strategies for subtype s-dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol Aug 22: 1736-1747.
20. He W, Yin C, Guo G, Jian g C, Wang F, Qiu H, Chen X, Rong R, Zhang B, Xia L (2013) Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med On col 30: 439.
21. Klinger MH Jelkmann W 2002 Role of blood platelets in infection and inflammation J Interferon Cytokine Res 22 913-922.
22. Koch A, Fohlin H, Sörenson S (200 9) Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 4: 326-332.
23. Kono SA, Heasley LE, Doebele RC, Camidge DR (2012) Adding to the mix: Fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets 12: 107-123.
24. Kraeim a J, Siesling S, Vliegen IM, Klaase JM, Ijzerman MJ (2013) Individual risk profiling for breast cancer recurrence: Towards tailored follow-up schemes. Br J Cancer 109: 866-871.
25. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, Park KJ, Roh MS, Kim SG, Kim HJ, Lee JH (2012) Clinical significance of preoperative neutrophillymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 17: 216-222.
26. Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH, Kim HJ (2012) Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma. BMC Cancer 13: 350.
27. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG, McMillan DC (2007) Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients w ith colorectal cancer. Br J Cancer 97: 1266-1270.
28. Liu HL, DU XH, Sun PM, Xiao CH, Xu YX, Li R (2013) Preoperative plateletlymphocyte ratio is an independent prognostic factor for resectable colorect al cancer. Nan Fang Yi Ke Da Xue Xue Bao 33: 70-73.
29. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29: 1949-1955.
30. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444.
31. Mohammed ZMA, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC (2012) The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with pr imary operable invasive ductal breast cancer. Br J Cancer 107: 864-873.
32. Nieto Y, Nawaz S, Shpall EJ, Bearman SI, Murphy J, Jones RB (2004) Long-term analysis and prospective validation of a prog nostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. Clin Cancer Res 10: 2609-2617.
33. Ownby HE, Roi LD, Isenberg RR, Brennan MJ (1983) Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 52: 126-130.
34. Pierce BL, Ballard-Barbash R, Berstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilli land FD, Sorensen BE, McTiernan A, Ulrich CM (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 21: 3437-3444.
35. Proctor MJ, Mor rison DS, Talwar D, Balmer SM, Fletcher CD, O?Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47: 2633-2641.
36. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T (2012) Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol On col 23: 265-273.
37. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY (2009) European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Lymphopenia as a prognostic factor for overall survival in advanced carcinoma s, sarcomas, and lymphomas. Cancer Res 69: 5383-5391.
38. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM (1997) Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182: 318-324.
39. Roxburgh CS, McMillan DC (2012) The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 38: 451-466.
40. Saghatchian M, Mook S, Pruneri G, Viale G, Glas AM, Guerin S, Cardoso F, Piccart M, Tursz T, Delaloge S, Van?t Veer L (2012) Additional prognostic value of the 70-gene signature (MammaPrint(s)) among breast cancer patients with 4-9 positive lymph nodes. Breast 22: 682-690.
41. Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A (2007) Paradoxical effects of cytokines in tumor immune surveillance and tumor escape. Cytokine Growth Factor Rev 18: 171-182.
42. Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH, Park SY (2013) Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109: 2705-2713.
43. Seretis C Seretis F Lagoudianakis E Politou M Gemenetzis G Salemis NS 2012 Enhancing the accuracy of platelet to lymphocyte ratio after adjustment for large platelet count: A pilot study in breast cancer patients. Int J Surg Oncol 2012 653608.
44. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P (2009) Preoperative platelet-lymphocyte ratio is an independent significant progn ostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197: 466-472.
45. Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP (2008) Prognosis of resected ampullary adeno carcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg 12: 1422-1428.
46. Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A (2014) The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer 110: 435-440.
47. Suzuki K, Aiura K, Ueda M, Ki tajima M (2004) The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. Pancreas 29: 132-140.
48. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Samonigg H, Maurer-Ertl W, Stojakovic T, Ploner F, Leithner A, Pichler M (2013) Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. Br J Cancer 109 : 2316-2322.
49. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH (2011) Tumor-infiltrating lymphocytes predict response to anthracyclinebased chemotherapy in estrogen receptor-negative breast cance r. Breast Cancer Res 13: R126.